Glenmede Trust’s Molecular Templates, Inc. MTEM Stock Holding History

Glenmede Trust’s Portfolio MTEM Stock Details MTEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,778	Closed	-$19K	–	1352
2022 Q3	$19K	Hold	1,778	–	–	﹤0.01%	1222
2022 Q2	$24K	Hold	1,778	–	–	﹤0.01%	1229
2022 Q1	$92K	Hold	1,778	–	–	﹤0.01%	1199
2021 Q4	$104K	Hold	1,778	–	–	﹤0.01%	1202
2021 Q3	$178K	Hold	1,778	–	–	﹤0.01%	1148
2021 Q2	$208K	Hold	1,778	–	–	﹤0.01%	1124
2021 Q1	$336K	Hold	1,778	–	–	﹤0.01%	954
2020 Q4	$250K	Hold	1,778	–	–	﹤0.01%	1006
2020 Q3	$291K	Sell	1,778 -1,066	-37%	-$190K	﹤0.01%	931
2020 Q2	$588K	Buy	2,844 +1,777	+167%	+$413K	﹤0.01%	730
2020 Q1	$223K	Hold	1,067	–	–	﹤0.01%	1161
2019 Q4	$223K	Hold	1,067	–	–	﹤0.01%	1161
2019 Q3	$105	Hold	1,067	–	–	﹤0.01%	1388
2019 Q2	$133	Hold	1,067	–	–	﹤0.01%	1311
2019 Q1	$92	Hold	1,067	–	–	﹤0.01%	1443
2018 Q4	$64	Buy	+1,067	New	+$74.5K	﹤0.01%	1497

Other funds holding MTEM

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust's MTEM Position: Q4 2022 in Review

Glenmede Trust sold out of Molecular Templates, Inc. (MTEM) in Q4 2022, closing a stake of 1,778 shares — an estimated $19K sold.

Glenmede Trust first reported a position in MTEM in Q4 2018 and held it in 16 quarters. The position peaked at $588K in Q2 2020. 50 funds tracked by Wall St. Rank hold MTEM as of Q4 2022.

Glenmede Trust reported no remaining Molecular Templates, Inc. position as of Q4 2022 after selling out during the quarter.
Glenmede Trust sold 1,778 Molecular Templates, Inc. shares in Q4 2022, an estimated $19K.
Glenmede Trust first reported a position in Molecular Templates, Inc. in Q4 2018 and held it in 16 quarters.
Glenmede Trust's Molecular Templates, Inc. position peaked at $588K in Q2 2020.
50 funds tracked by Wall St. Rank held Molecular Templates, Inc. as of Q4 2022.

Based on Glenmede Trust's 13F filing for Q4 2022, filed 14 Feb 2023.